Home
Resource
Phytochemicals and repurposed, FDA approved drugs show potential as a cost effective combination treatment for ovarian cancer
PDF
PDF format is widely accepted and good for printing.
Plug-in required
PDF-1(1.02 MB)
Citation & Export
View Usage Statistics
Staff View

Citation & Export
Hide

Simple citation

Christensen, Chase Tyler. Phytochemicals and repurposed, FDA approved drugs show potential as a cost effective combination treatment for ovarian cancer. Retrieved from https://doi.org/doi:10.7282/t3-7yq9-z482

Export

Click here for information about Citation Management Tools at Rutgers.

Statistics
Hide

Description

TitlePhytochemicals and repurposed, FDA approved drugs show potential as a cost effective combination treatment for ovarian cancer
NameChristensen, Chase Tyler (author); Fong, Dunne (chair); Firestein, Bonnie (internal member); Kwan, Kelvin (internal member); Rutgers University; School of Graduate Studies
Date Created2020
Other Date2020-05 (degree)
SubjectCurcumin, Ovaries -- Cancer -- Treatment, Cell and Developmental Biology
Extent1 online resource (viii, 60 pages) : illustrations
DescriptionA cancer diagnosis is an event that countless people fear. Besides the debilitating effects of the disease itself, treatments also take a substantial toll on a patient’s health as well as their finances. Even successful treatments cause survivors to live with the constant concern that their illness will return. When relapse does occur, prior therapies may no longer be an option due to cancer cells gaining resistance under the cancer stem cell model. As such, new therapies must be developed to once again aid patients enter a second battle for their lives.

Phytochemicals, for example curcumin, are plant derived molecules that have shown promise as a potential treatment for ovarian and other cancers. In addition to phytochemicals, repurposed FDA approved drugs are another option being explored by researchers. Studying drugs that are already approved for other indications will reduce the time and cost required to develop new therapies. For people living with limited access to medical care due to financial matters, low cost treatment for deadly diseases is highly desired.

By conducting a series of in vitro alamarBlue cell viability assays, this paper aims to provide evidence that niclosamide, an off patent FDA approved drug for parasitic tapeworm infection, and curcumin, a phytochemical derived from turmeric, hold the potential to be low cost therapies for women suffering from ovarian cancer. In addition, using these molecules in combination has shown synergistic properties that act to decrease cell viability of SKOV3 ovarian cancer cells. Under the cancer stem cell model, cases of relapse may be reduced by using niclosamide and curcumin to target resistant subpopulations of cancer cells left after conventional therapies are administered.
NoteM.S.
NoteIncludes bibliographical references
Genretheses, ETD graduate
Persistent URLhttps://doi.org/doi:10.7282/t3-7yq9-z482
LanguageEnglish
CollectionSchool of Graduate Studies Electronic Theses and Dissertations
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.
Version 8.5.5
Rutgers University Libraries - Copyright ©2024